Novo Nordisk Annual Report 2018 accounts for our financial, social and environmental performance during the year in one integrated report.
The innovation level required to develop new commercially viable medicines is increasing. To continue delivering life-changing treatments for people living with serious chronic diseases, Novo Nordisk research and development organisation embraces new ways of working and invites even more partners to join us, so we can increase innovation together.
Read more in the Annual Report
While many people are accustomed to taking a daily tablet, for example as a vitamin supplement, many are reluctant to injecting themselves. Still, the vast majority of patients on Novo Nordisk diabetes products are relying on daily injections to manage their disease. For some of them, this is about to change.
Read more in the Annual Report
Around 13% of the world’s adult population live with obesity. This translates into 650 million people. And the prevalence is increasing. Yet, less than 2% of them – 11 million – today receive pharmacological therapy for this disease. Novo Nordisk is determined to tackle this and has upped its commitment and investments to make obesity a healthcare priority and provide innovative treatment solutions to people with obesity.
Read more in the Annual Report
A shortened Danish version of the Annual Report 2018, consisting of the Management review and excerpts from the consolidated statements. In the event of any discrepancies the full statutory Annual Report shall prevail..
The Form 20-F is filed using a standardised reporting form so that investors can evaluate the company alongside US domestic equities. It is an annual reporting requirement by the US Securities and Exchange Commission (SEC) for foreign private issuers with equity shares listed on exchanges in the United States.
Corporate Governance Report 2018 is a requirement according to the Danish Financial Statements Act. Reporting of compliance with Danish Corporate Governance Recommendations.
The remuneration report includes the total remuneration received by each member of the Board of Directors and the Executive Management of Novo Nordisk A/S from 2016 to 2018.
The UK Modern Slavery Act 2015 requires companies in scope to produce a statement which must set out what steps they have taken during the financial year to ensure that modern slavery is not occurring in their supply chains or in their own organisations.
